Robert Davey, PhD
Professor
Boston University School of Medicine
Dept of Microbiology

PhD, University of Adelaide




Dr. Robert Davey, PhD is a currently a Professor of Microbiology at the Boston University School of Medicine. Dr. Davey received his doctorate in Microbiology and Immunology at the University of Adelaide in Australia. He continued his training as a Postdoctoral Fellow at the Howard Hughes Medical Institute and then at the Division of Hematology, both with Dr. James Cunningham at Brigham and Women's Hospital and Harvard Medical School.

Dr. Davey's first academic appointment was as an Instructor in Medicine at Harvard. He then held an Assistant Professor position which he got promoted to Adjunct Associate Professor at the Department of Microbiology and Immunology at the University of Texas Medical Branch.

Dr. Davey was also a Ewing Halsell Scholar and Scientist at the Department of Virology and Immunology at the Texas Biomedical Research Institute. As a Scientist at the Texas Biomedical Research Institute, Dr. Davey's work was focused on identification of cellular factors important for establishing infection by filovirus and bunyaviruses. His work has culminated in a deeper understanding of the entry and cell signaling pathways that are used by these viruses to penetrate the cell membrane and establish infection. His work with Ebolavirus has been published in the high-impact journals PLoS Pathogens, PNAS and a new article on host factor dependence in Science that was featured on the cover page. Dr. Davey’s group works collaboratively with a number of groups providing sophisticated molecular biology and cell biology techniques for the study of pathogenic viruses including Ebolavirus for which the lab mainly works. He has developed high throughput screening techniques for Ebolavirus. He also performs contract work testing drugs and compounds for ebolavirus infection inhibition. His team is well trained in ABSL4 procedures and have been working with Ebolavirus since 2006.

From 2015-2017, Dr. Davey held the role of Interim Chair in the Department of Virology and Immunology at the Texas Biomedical Research Institute. He is also Director of ABSL4 at the Texas Biomedical Research Institute.

Faculty
Boston University
National Emerging Infectious Disease Lab


Member
Boston University School of Medicine
Evans Center for Interdisciplinary Biomedical Research


Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences



2015 San Antonio business journal: Outstanding medical researcher, Healthcare heroes awards
2005 UTMB Graduate school teaching award


Antiviral Lead Identification to Treat Filovirus Infections
08/12/2019 - 07/31/2023 (Subcontract PI)
Purdue University NIH NIAID
5R01AI128364-02

STTR Phase I: Aminomethyl benzamides as novel anti Ebola agents
08/16/2019 - 07/31/2022 (Subcontract PI)
Chicago BioSolutions, Inc. NIH NIAID
5R42AI126971-04

Neutralization and binding of antibody to virus by Regeneron antibodies
07/08/2020 - 06/30/2022 (Subcontract PI)
Regeneron Pharmaceuticals, Inc. HHS ASPR BARDA
HHSO100201700020C

Structural and Functional Characterization of the Ebola Virus Replication Complex (Core C)
07/01/2019 - 06/30/2021 (Subcontract PI)
The Washington University NIH NIAID
5P01AI120943-04

Structural and Functional Characterization of the Ebola Virus Replication Complex
07/01/2018 - 06/30/2021 (Subcontract PI)
The Washington University NIH NIAID
5P01AI120943-05

HTS for identification and evaluation of efficacy for therapeutics against SARS-CoV-2 infection
05/01/2020 - 04/30/2021 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School China Evergrande Gr


Emerging virus-host cell protein interaction networks
08/01/2018 - 03/31/2021 (Subcontract PI)
Purdue University NIH NIAID
5R01AI114814-05

Small molecule inhibitors of Ebola virus polymerase function
08/01/2018 - 01/31/2021 (Subcontract PI)
Georgia State University NIH NIAID
5R01AI125453-04

Advanced development of a viral entry inhbitor as a therapeutic for arenavirus hemorrhagic fever
03/01/2020 - 12/31/2020 (Subcontract PI)
Kineta, Inc. NIH NIAID
5R01AI141102-02

Modeling Filovirus Infection of and Trafficking through Skin
08/01/2018 - 07/31/2020 (Subcontract PI)
The University of Iowa NIH NIAID
5R01AI134733-02



Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Morselli Gysi D, do Valle Í, Zitnik M, Ameli A, Gan X, Varol O, Ghiassian SD, Patten JJ, Davey RA, Loscalzo J, Barabási AL. Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci U S A. 2021 05 11; 118(19). PMID: 33906951
     
  2. Mena EL, Donahue CJ, Vaites LP, Li J, Rona G, O'Leary C, Lignitto L, Miwatani-Minter B, Paulo JA, Dhabaria A, Ueberheide B, Gygi SP, Pagano M, Harper JW, Davey RA, Elledge SJ. ORF10-Cullin-2-ZYG11B complex is not required for SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2021 04 27; 118(17). PMID: 33827988
     
  3. Patten JJ, Keiser PT, Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, Do Valle I, Geoghegan-Barek K, Anantpadma M, Berrigan JL, Jalloh S, Ayazika T, Wagner F, Zitnik M, Ayehunie S, Anderson D, Loscalzo J, Gummuluru S, Namchuk MN, Barabasi AL, Davey RA. Multidose evaluation of 6,710 drug repurposing library identifies potent SARS-CoV-2 infection inhibitors In Vitro and In Vivo. bioRxiv. 2021 Apr 22.View Related Profiles. PMID: 33907750
     
  4. Novelli G, Liu J, Biancolella M, Alonzi T, Novelli A, Patten JJ, Cocciadiferro D, Agolini E, Colona VL, Rizzacasa B, Giannini R, Bigio B, Goletti D, Capobianchi MR, Grelli S, Mann J, McKee TD, Cheng K, Amanat F, Krammer F, Guarracino A, Pepe G, Tomino C, Tandjaoui-Lambiotte Y, Uzunhan Y, Tubiana S, Ghosn J, Notarangelo LD, Su HC, Abel L, Cobat A, Elhanan G, Grzymski JJ, Latini A, Sidhu SS, Jain S, Davey RA, Casanova JL, Wei W, Pandolfi PP. Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell Death Dis. 2021 03 24; 12(4):310. PMID: 33762578
     
  5. Wang LL, Palermo N, Estrada L, Thompson C, Patten JJ, Anantpadma M, Davey RA, Xiang SH. Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site. Antiviral Res. 2021 May; 189:105059. PMID: 33705865
     
  6. Keiser PT, Anantpadma M, Staples H, Carrion R, Davey RA. Automation of Infectious Focus Assay for Determination of Filovirus Titers and Direct Comparison to Plaque and TCID50 Assays. Microorganisms. 2021 Jan 12; 9(1). PMID: 33445537
     
  7. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash PEA, Verma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, Wolozin BL, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A. Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Mol Cell. 2021 Jan 07; 81(1):212.View Related Profiles. PMID: 33417854
     
  8. Gorgulla C, Padmanabha Das KM, Leigh KE, Cespugli M, Fischer PD, Wang ZF, Tesseyre G, Pandita S, Shnapir A, Calderaio A, Gechev M, Rose A, Lewis N, Hutcheson C, Yaffe E, Luxenburg R, Herce HD, Durmaz V, Halazonetis TD, Fackeldey K, Patten JJ, Chuprina A, Dziuba I, Plekhova A, Moroz Y, Radchenko D, Tarkhanova O, Yavnyuk I, Gruber C, Yust R, Payne D, Näär AM, Namchuk MN, Davey RA, Wagner G, Kinney J, Arthanari H. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. iScience. 2021 Feb 19; 24(2):102021. PMID: 33426509
     
  9. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash PEA, Verma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, Wolozin BL, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A. Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Mol Cell. 2020 12 17; 80(6):1104-1122.e9.View Related Profiles. PMID: 33259812; DOI: 10.1016/j.molcel.2020.11.028;
     
  10. Cooper L, Schafer A, Li Y, Cheng H, Medegan Fagla B, Shen Z, Nowar R, Dye K, Anantpadma M, Davey RA, Thatcher GRJ, Rong L, Xiong R. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 10 08; 63(19):11085-11099. PMID: 32886512
     
Showing 10 of 100 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 100 publications over 25 distinct years, with a maximum of 9 publications in 2020

YearPublications
19911
19922
19961
19972
19981
19991
20011
20041
20052
20068
20073
20084
20092
20104
20116
20126
20134
20147
20157
20165
20173
20188
20194
20209
20218
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Marburg
Ebolavirus
ABSL4
Virology
Immunology
bunyaviruses
arenaviruses
Junin virus
Lassa Fever
Filoviruses
Contact for Mentoring:

620 Albany Street
Boston MA 02118
Google Map


Davey's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department